Logix Biosciences, Inc. Announces Appointment of Amy Broidrick to Board of Directors

MONTEREY, Calif.--(BUSINESS WIRE)--Logix Biosciences, a biopharmaceutical company focused on the discovery and development of a pipeline of precision therapeutics and companion diagnostics for allergy relief, protection against infectious diseases, and antimicrobial resistance (AMR) today announced the addition of Amy Broidrick to its Board of Directors. Broidrick's experience includes key roles in the successful commercialization of numerous therapeutics, including marketing and launching blockbuster and specialty drugs such as Zetia, VYTORIN, and Celebrex.

"Amy brings to the Board 29 years of strategic, commercial, and operational experience in the pharmaceutical industry, and we are thrilled to welcome her to our Board of Directors," said Gavin Gear, CEO of Logix Biosciences. "Leveraging her expertise in strategy, corporate development, marketing and commercialization, and business innovation with global and US organizations will be invaluable as we execute our business strategy and advance our therapeutics development programs.”

Broidrick's career has been marked by her global and US impact. Amy is currently serving as a strategic advisor to public and private US and international pharmaceutical and biotech companies and start-ups. In 2020 she was appointed as an independent, non-executive Director to the Board of Qualigen Therapeutics, a Nasdaq listed clinical stage biotechnology company focused on developing rare cancer therapeutics, where she later served as President, and Board Director from 2021-2023. Prior to Qualigen, she served as Senior Vice President and Head of Corporate Development at Viking Therapeutics responsible for US and global corporate and business development functions. Previously, she was Vice President and Head of Global Marketing Excellence and Business Innovation at EMD Serono (part of Merck KGaA), leading global and country brand and launch planning, and strategic transformation initiatives. From 2010 to 2012, Broidrick was Vice President and Head of Marketing and Commercialization at Arena Pharmaceuticals, overseeing commercial planning of a first-in-class obesity drug candidate, and portfolio planning. She also held various roles at Merck & Co., including Global Brand Leader with P&L accountability, and leading new products marketing planning across brands and the pipeline for Asia Pacific.

Broidrick holds a BA from Fairleigh Dickinson University, completed studies at Wroxton College in England, and post-graduate coursework at Fairleigh Dickinson.

"I am honored and excited to join the Board of Directors at Logix at this mission-critical time as the company develops it’s pipeline of precision therapeutics and companion diagnostics," said Broidrick.

Logix Biosciences is a biopharmaceutical company focused on discovering and developing precision therapeutics and companion diagnostics for allergy relief, protection against infectious diseases, and antimicrobial resistance (AMR).